Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma
BackgroundRadiofrequency ablation (RFA) is the primary curative treatment for hepatocellular carcinoma (HCC) patients who are not eligible for surgery. However, the effects of RFA on the global tumor immune response remain unclear.MethodIn this study, we examined the phenotypic and functional change...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1339213/full |
| _version_ | 1827370459689123840 |
|---|---|
| author | Yang Zhao Yang Zhao Tongwang Yang Tongwang Yang Yabo Ouyang Yabo Ouyang Wei Rao Kai Liu Kai Liu Jiasheng Zheng Fudong Lv Ying Shi Ying Shi Feng Wang Dongjie Liu Dongjie Liu Luxin Qiao Luxin Qiao Zhenying Xia Yushi Zhang Dexi Chen Dexi Chen Dexi Chen Wenjing Wang Wenjing Wang |
| author_facet | Yang Zhao Yang Zhao Tongwang Yang Tongwang Yang Yabo Ouyang Yabo Ouyang Wei Rao Kai Liu Kai Liu Jiasheng Zheng Fudong Lv Ying Shi Ying Shi Feng Wang Dongjie Liu Dongjie Liu Luxin Qiao Luxin Qiao Zhenying Xia Yushi Zhang Dexi Chen Dexi Chen Dexi Chen Wenjing Wang Wenjing Wang |
| author_sort | Yang Zhao |
| collection | DOAJ |
| description | BackgroundRadiofrequency ablation (RFA) is the primary curative treatment for hepatocellular carcinoma (HCC) patients who are not eligible for surgery. However, the effects of RFA on the global tumor immune response remain unclear.MethodIn this study, we examined the phenotypic and functional changes in peripheral blood mononuclear cells (PBMCs) from recurrent HCC patients who had undergone two RFA treatments using mass cytometry and high-throughput mRNA assays. ResultsWe observed significant increase in monocytes and decrease in T cell subpopulations three days after the first RFA treatment and three days after the second RFA treatment. The down-regulation of GZMB, GZMH, GZMK, and CD8A, which are involved in the cytotoxic function of T cells, was observed following RFA. Furthermore, the population of CD8 effector and memory T cells (CD8 Teff and CD8 Tem) significantly decreased after RFA. The expression of CD5 and CD161 in various T cell subpopulations also showed significant reductions. Additionally, elevated secretion of VEGF was observed in monocytes, B cells, regulatory T cells (Tregs), and CD4 naive T cells. ConclusionIn recurrent HCC patients, serum components derived from radiofrequency therapy can enhance the antigen-presenting capacity of monocytes. However, they also inhibit the anti-cancer immune response by reducing the population of CD8 effector and memory T cells and suppressing the activation of T cells, as well as down-regulating the expression of CD161 and CD5 in various T cell subpopulations. These tumor-derived components also contribute to an immunosuppressive microenvironment by promoting the secretion of VEGF in monocytes, Tregs, B cells, and CD4 naive T cells. |
| first_indexed | 2024-03-08T10:14:38Z |
| format | Article |
| id | doaj.art-6eaf9cff89c54b47beba70bf1b4970cc |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T10:14:38Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6eaf9cff89c54b47beba70bf1b4970cc2024-01-29T04:27:35ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011510.3389/fimmu.2024.13392131339213Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinomaYang Zhao0Yang Zhao1Tongwang Yang2Tongwang Yang3Yabo Ouyang4Yabo Ouyang5Wei Rao6Kai Liu7Kai Liu8Jiasheng Zheng9Fudong Lv10Ying Shi11Ying Shi12Feng Wang13Dongjie Liu14Dongjie Liu15Luxin Qiao16Luxin Qiao17Zhenying Xia18Yushi Zhang19Dexi Chen20Dexi Chen21Dexi Chen22Wenjing Wang23Wenjing Wang24Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaThe Affiliated Hospital of Qingdao University, Organ Transplantation Center, Qingdao, Shandong, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaThe Affiliated Hospital of Qingdao University, Organ Transplantation Center, Qingdao, Shandong, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaThe Affiliated Hospital of Qingdao University, Organ Transplantation Center, Qingdao, Shandong, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaThe Affiliated Hospital of Qingdao University, Organ Transplantation Center, Qingdao, Shandong, ChinaDepartment of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaThe Affiliated Hospital of Qingdao University, Organ Transplantation Center, Qingdao, Shandong, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaBeijing YouAn Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing, ChinaBeijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer, Beijing, ChinaBackgroundRadiofrequency ablation (RFA) is the primary curative treatment for hepatocellular carcinoma (HCC) patients who are not eligible for surgery. However, the effects of RFA on the global tumor immune response remain unclear.MethodIn this study, we examined the phenotypic and functional changes in peripheral blood mononuclear cells (PBMCs) from recurrent HCC patients who had undergone two RFA treatments using mass cytometry and high-throughput mRNA assays. ResultsWe observed significant increase in monocytes and decrease in T cell subpopulations three days after the first RFA treatment and three days after the second RFA treatment. The down-regulation of GZMB, GZMH, GZMK, and CD8A, which are involved in the cytotoxic function of T cells, was observed following RFA. Furthermore, the population of CD8 effector and memory T cells (CD8 Teff and CD8 Tem) significantly decreased after RFA. The expression of CD5 and CD161 in various T cell subpopulations also showed significant reductions. Additionally, elevated secretion of VEGF was observed in monocytes, B cells, regulatory T cells (Tregs), and CD4 naive T cells. ConclusionIn recurrent HCC patients, serum components derived from radiofrequency therapy can enhance the antigen-presenting capacity of monocytes. However, they also inhibit the anti-cancer immune response by reducing the population of CD8 effector and memory T cells and suppressing the activation of T cells, as well as down-regulating the expression of CD161 and CD5 in various T cell subpopulations. These tumor-derived components also contribute to an immunosuppressive microenvironment by promoting the secretion of VEGF in monocytes, Tregs, B cells, and CD4 naive T cells. https://www.frontiersin.org/articles/10.3389/fimmu.2024.1339213/fullmass cytometryradiofrequency ablationrecurrent hepatocellular carcinomaPBMCimmunosuppresion |
| spellingShingle | Yang Zhao Yang Zhao Tongwang Yang Tongwang Yang Yabo Ouyang Yabo Ouyang Wei Rao Kai Liu Kai Liu Jiasheng Zheng Fudong Lv Ying Shi Ying Shi Feng Wang Dongjie Liu Dongjie Liu Luxin Qiao Luxin Qiao Zhenying Xia Yushi Zhang Dexi Chen Dexi Chen Dexi Chen Wenjing Wang Wenjing Wang Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma Frontiers in Immunology mass cytometry radiofrequency ablation recurrent hepatocellular carcinoma PBMC immunosuppresion |
| title | Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma |
| title_full | Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma |
| title_fullStr | Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma |
| title_full_unstemmed | Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma |
| title_short | Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma |
| title_sort | radiofrequency ablation plays double role in immunosuppression and activation of pbmcs in recurrent hepatocellular carcinoma |
| topic | mass cytometry radiofrequency ablation recurrent hepatocellular carcinoma PBMC immunosuppresion |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1339213/full |
| work_keys_str_mv | AT yangzhao radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yangzhao radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT tongwangyang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT tongwangyang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yaboouyang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yaboouyang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT weirao radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT kailiu radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT kailiu radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT jiashengzheng radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT fudonglv radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yingshi radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yingshi radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT fengwang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT dongjieliu radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT dongjieliu radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT luxinqiao radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT luxinqiao radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT zhenyingxia radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT yushizhang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT dexichen radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT dexichen radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT dexichen radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT wenjingwang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma AT wenjingwang radiofrequencyablationplaysdoubleroleinimmunosuppressionandactivationofpbmcsinrecurrenthepatocellularcarcinoma |